Search results
-
AstraZeneca doubles down on GPC3
… which had yielded phase 1 safety and biomarker data at ESMO 2023. The company didn’t give a reason for its …
- 06/16/2025 - 13:14 -
Mersana shows that B7-H4 expression matters
… basis of a 29% ORR among 28 TNBC patients, reported at ESMO 2023 . However, while this Chinese trial enrolled …
- 06/30/2025 - 12:24 -
Triple meeting 2024 – Zai Lab impresses in small cell
… Presentation venue Triple meeting 2024 ESMO 2023 ASCO 2024 ORR 74% (14/19)* 40% …
- 10/29/2024 - 13:27 -
Merck and Daiichi look beyond small cell with ifinatamab
… Safety, antitumour activity Data at WCLC & ESMO 2023: ORR 52% in SCLC; 21% in ESCC; 25% in mCRPC; 31% …
- 10/24/2024 - 13:51 -
No easy ride for Turnstone
… TIL BioNTech BNT221 (ex Neon) disappointed at ESMO 2023 Personalised neoantigen-specific TIL …
- 10/15/2024 - 14:25 -
Triple meeting 2024 – can Revolution succeed where others stumbled?
… efforts to hit this target have so far fallen short: at ESMO 2023, Jiangsu HengRui’s inhibitor HRS-4642 produced …
- 10/25/2024 - 14:51 -
KRAS strikes back
… Jiangsu Hengrui’s inhibitor HRS-4642 disappointing at ESMO 2023, and Astellas’s degrader ASP3082 underwhelming …
- 10/01/2024 - 14:30 -
Dato sees double survival trouble
… all-comers was 12.9mth vs 11.8mth (HR=0.94, p=0.530); **at ESMO 2023 interim OS was described as numerically favourable …
- 09/24/2024 - 15:07 -
ESMO 2024 – Torl challenges BioNTech in Claudin6
… of BNT211 was deemed to be toxic by the discussant at ESMO 2023 , Centre Léon Bérard’s Dr Philippe Cassier. …
- 09/17/2024 - 12:26 -
ESMO 2024 – Astra’s B7-H4 effort underwhelms
… inhibitor 6 Ph1 China study in solid tumours ESMO 2023: 29% ORR in 28 TNBC pts XMT-1660 Mersana …
- 09/15/2024 - 08:35
